



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	3	Attorney Docket Number	03-04US
-------	---	----	---	------------------------	---------

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
/TH/		US-5,428,708 5,482,706	Issued 6-27-1995	Coflexip Takeda Chemical Industries, Ltd.	
		US-5,482,931	Issued 01-09-1996	Ferring AB	
		US-5,503,827	Issued 04-02-1996	Boehringer Mannheim GmbH	
		US-5,508,260	Issued 04-16-1996	Amylin Pharmaceuticals, Inc.	
		US-5,514,365	Issued 05-07-1996	Schlapparelli Salute S.P.A.	
		US-5,527,771	Issued 06-18-1996	Amylin Pharmaceuticals, Inc.	
		US-5,554,378	Issued 09-10-1996	Takeda Chemical Industries,	
		US-5,565,423	Issued 10-15-1996	Hoechst Aktiengesellschaft	
		US-5,574,006	Issued 11-12-1996	Dott Research Laboratory	
		US-5,576,016	Issued 11-19-1996	Pharmos Corporation	
		US-5,578,324	Issued 11-26-1996	Teijin Limited	
		US-5,603,943	Issued 02-18-1997	Dott Research Laboratory	
		US-5,654,000	Issued 08-05-1997	Poli Industria Chimica S.p.A.	
		US-5,681,811	Issued 10-28-1997	Protein Delivery, Inc.	
		US-5,693,608	Issued 12-02-1997	Bechgaard International Research and Development	
		US-5,719,122	Issued 02-17-1998	SmithKline Beecham Farmaceutici S.p.A.	
		US-5,725,852	Issued 03-10-1998	Takeda Chemical Industries,	
		US-5,725,871	Issued 03-10-1998	Danbiosyst UK Limited	
		US-5,733,569	Issued 03-31-1998	Novartis Corporation	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
		GB 2 177 914 A	02-04-1987	Chugai Seiyaku Kabushiki Kaisha		
		EP 0 358 234 A2	03-14-1990	Rorer International (Overseas) Inc.		
		EP 0 371 010 A1	05-30-1990	Yamanouchi Pharmaceutical Co. Ltd.		
		EP 0 418 697 A1	03-27-1991	Esseit's.a.s. Laboratorio Chimico Farmaco Biologico Di A. levoli & C.		
		EP 0 471 618 A1	08-12-1991	Toyo Jozo Co., Ltd.		
↓		EP 0 489 217 A1	06-10-1992	DR. A. Tosi Farmaceutici S.R.L.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

**Complete If Known**

Application Number	10/805,788
Filing Date	3/22/2004
First Named Inventor	Quay et al.
Art Unit	1654
Examiner Name	Thomas Sweeney Heard

Attorney Docket Number 03-04US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
/TH/		US-5,482,706	Issued 6-27-1995	Takeda Chemical Industries, Ltd.	
		US-5,482,931	Issued 01-09-1996	Ferring AB	
		US-5,503,827	Issued 04-02-1996	Boehringer Mannheim GmbH	
		US-5,508,260	Issued 04-18-1996	Amylin Pharmaceuticals, Inc.	
		US-5,514,365	Issued 05-07-1996	Schiapparelli Salute S.P.A.	
		US-5,527,771	Issued 06-18-1996	Amylin Pharmaceuticals, Inc.	
		US-5,554,378	Issued 09-10-1996	Takeda Chemical Industries, Ltd.	
		US-5,565,423	Issued 10-15-1996	Hoechst Aktiengesellschaft	
		US-5,574,006	Issued 11-12-1996	Dott Research Laboratory	
		US-5,576,016	Issued 11-19-1996	Phamos Corporation	
		US-5,578,324	Issued 11-26-1996	Teijin Limited	
		US-5,603,943	Issued 02-18-1997	Dott Research Laboratory	
		US-5,654,000	Issued 08-05-1997	Poli Industria Chimica S.p.A.	
		US-5,681,811	Issued 10-28-1997	Protein Delivery, Inc.	
		US-5,693,608	Issued 12-02-1997	Bechgaard International Research and Development A/S	
		US-5,719,122	Issued 02-17-1998	SmithKline Beecham Farmaceutici S.p.A.	
		US-5,725,852	Issued 03-10-1998	Takeda Chemical Industries, Ltd.	
		US-5,725,871	Issued 03-10-1998	Danbiosyst UK Limited	
		US-5,733,569	Issued 03-31-1998	Novartis Corporation	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		GB 2 177 914 A	02-04-1987	Chugai Seiyaku Kabushiki Kaisha		
		EP 0 358 234 A2	03-14-1990	Rorer International (Overseas) Inc.		
		EP 0 371 010 A1	05-30-1990	Yamanouchi Pharmaceutical Co. Ltd.		
		EP 0 418 697 A1	03-27-1991	Esseit s.a.s. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C.		
		EP 0 471 618 A1	08-12-1991	Toyo Jozo Co., Ltd.		
		EP 0 489 217 A1	06-10-1992	DR. A. Tosi Farmaceutici S.R.L.		

Examiner Signature	/Thomas Heard/	Date Considered	05/29/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.